Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models.

Communications biology - 19 Feb 2021

Jin Jack Wuyang, Fan Xuelai, Del Cid-Pellitero Esther, Liu Xing-Xing, Zhou Limin, Dai Chunfang, Gibbs Ebrima, He Wenting, Li Hongjie, Wu Xiaobin, Hill Austin, Leavitt Blair R, Cashman Neil, Liu Lidong, Lu Jie, Durcan Thomas M, Dong Zhifang, Fon Edward A, Wang Yu Tian

Abstract excerpt

Convincing evidence supports the premise that reducing α-synuclein levels may be an effective therapy for Parkinson's disease (PD); however, there has been lack of a clinically applicable α-synuclein reducing therapeutic strategy. This study was undertaken to develop a blood-brain barrier and plasma membrane-permeable α-synuclein knockdown peptide, Tat-βsyn-degron, that may have therapeutic potential. The peptide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Antiparkinson Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Behavior, Animal

Share to Motor Activity

Share to Parkinson Disease

Share to Proteasome Endopeptidase Complex

Share to Proteolysis

Share to Rats, Sprague-Dawley

Source

Open in PubMed Open full text

Identifiers

PMID: 33608634
DOI: 10.1038/s42003-021-01746-6
PMCID: PMC7895943

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models.PMID 33608634Read ↗

The good and bad of therapeutic strategies that directly target α‐synucleinSemantic proximity Read ↗

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerationsSemantic proximity Read ↗

Modulating the Amyloidogenesis of α-Synuclein.Semantic proximity Read ↗

Inhibition of α-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson’s diseaseSemantic proximity Read ↗

In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategiesSemantic proximity Read ↗

Molecular properties and diagnostic potential of monoclonal antibodies targeting cytotoxic α-synuclein oligomersSemantic proximity Read ↗

A <i>de novo</i> compound targeting α-synuclein improves deficits in models of Parkinson's diseaseSemantic proximity Read ↗

Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.Semantic proximity Read ↗

Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies.Semantic proximity Read ↗

Suppression and modulation mechanism underlying the flavonoid-induced inhibition of fibrillation of α-synucleinSemantic proximity Read ↗

Loss in Toxic Function of Aggregates of α -Synuclein Mutants by a β-Synuclein Derived Peptide.Semantic proximity Read ↗

The aggregation of α-synuclein and its inhibtionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.